Amgen Inc. has agreed to pay $24.9 million to resolve allegations that the company violated the False Claims Act by paying kickbacks. According to the allegations, Amgen paid kickbacks in the form of rebates to long-term care pharmacies, including Omnicare Inc., in order to encourage those pharmacies to switch Medicare and Medicaid patients to its anemia drug Aranesp. The case was initiated by a whistleblower.

Read the entire press release, “Amgen to Pay U.S. $24.9 Million to Resolve False Claims Act Allegations”